Details for New Drug Application (NDA): 208429

NDA 208429 describes IMATINIB MESYLATE, which is a drug marketed by Amneal Pharms, Apotex, Chartwell Rx, Cspc Ouyi, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Hikma, Mylan, Natco Pharma Ltd, Novitium Pharma, Qilu Pharm Hainan, Shilpa, Sun Pharm, Teva Pharms Usa, and Zydus Pharms, and is included in sixteen NDAs. It is available from nineteen suppliers. Additional details are available on the IMATINIB MESYLATE profile page.

The generic ingredient in IMATINIB MESYLATE is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.

Summary for 208429

Tradename:	IMATINIB MESYLATE
Applicant:	Chartwell Rx
Ingredient:	imatinib mesylate
Patents:	0

Pharmacology for NDA: 208429

Mechanism of Action

Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors

Medical Subject Heading (MeSH) Categories for 208429

Antineoplastic Agents

Protein Kinase Inhibitors

Suppliers and Packaging for NDA: 208429

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
IMATINIB MESYLATE	imatinib mesylate	TABLET;ORAL	208429	ANDA	Chartwell RX, LLC	62135-658	62135-658-90	90 TABLET, FILM COATED in 1 BOTTLE (62135-658-90)
IMATINIB MESYLATE	imatinib mesylate	TABLET;ORAL	208429	ANDA	Chartwell RX, LLC	62135-659	62135-659-30	30 TABLET, FILM COATED in 1 BOTTLE (62135-659-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 100MG BASE
Approval Date:	Jan 17, 2019	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 400MG BASE
Approval Date:	Jan 17, 2019	TE:	AB	RLD:	No

Complete Access Available with Subscription